Navigation Links
Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
Date:11/23/2007

AMSTERDAM, November 23 /PRNewswire/ -- Kiadis Pharma announces today that there will be three presentations on its products ATIR and Rhitol in poster sessions at the 2007 Annual Meeting of the American Society of Hematology (ASH) December 8-11 in Atlanta, Georgia, USA. Data will be presented from the companies ongoing clinical study on ATIR by its principal investigator Dr. Denis Claude Roy, who also presents data on the functionality of Rhitol. In addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the NIH.

ATIR: presentation of clinical phase I/II study on mismatched transplantations by Dr. Denis-Claude Roy

Title poster: "Phase I/II clinical trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher doses of Donor Lymphocyte Infusions depleted of Alloreactive Cells using ATIR may improve outcome without causing GvHD

- Abstract #2976; Poster 2976, Board #195-III (10 December,5-7 pm)

Dr. Denis Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "Our results indicate that the post-transplant infusion of a ATIR-PDT treated DLI is feasible, does not induce acute GVHD, and suggests a clinical benefit for patients receiving the highest DLI doses to accelerate T cell reconstitution. This PDT strategy represents an appealing alternative for older patients and those at high risk for GVHD"

Rhitol: presentation on functionality of Rhitol in chronic GvHD by Dr. Denis-Claude Roy

Title poster: " anti-Chronic Graft Versus Host Disease activity through a regulatory T Cell dependent mechanism after photodynamic therapy.

- Abstract #3280; Poster 3280; Board #499-III (10 December,5-7 pm)

Dr. Denis-Claude Roy head of Stem Cell Transplantation Unit, Hospital Maisonneuve-Rosemont, Montreal, Canada: "our results demonstrate that TH9402 PDT not only eliminates activated T cells, but preserves Tregs, with the functional ability to inhibit residual alloreactive cGVHD cells. This inhibitory effect requires live effector Tregs, secretion of IL-10 and TGF-β expression. With such dual effector mechanisms, photopheresis using TH9402 should translate into improved treatment efficacy and enhanced quality of life for patients with chronic GVHD"

Presentation of independent NIH study of Kiadis Pharma product ATIR Dr. Stephan Mielke

Title poster: "Successful Translation of a GMP-Based, Clinical Scale Selective Allodepletion Approach for Matched Donor-Recipient Pairs from Bench-to-Bedside"

- Abstract #3279; Poster 3279, board #499-III (10 December, 5-7 pm)

For the complete press release go to: http://www.kiadis.com/news/item/Kiadis_Pharma_presents_ATIR_and_Rhitol_data _a t_ASH/33

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists)


'/>"/>
SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: